首页|Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer

Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer

扫码查看
原文链接
  • NSTL
  • Elsevier
Objective: Pyrotinib, a new oral irreversible pan-ErbB tyrosine kinase inhibitor (TKI), has been approved in China for the treatment of HER2-positive advanced or metastatic breast cancer. This study aimed to conduct a population pharmacokinetics (PK) analysis of pyrotinib and to evaluate the impact of patient characteristics on pyrotinib's PK.

PyrotinibTyrosine kinase inhibitorPopulation pharmacokineticsMonte Carlo simulationHER2-positiveBreast cancer

Wen, Hai-ni、Liu, Yi-xi、Xu, Da、Zhao, Kai-jing、Jiao, Zheng

展开 >

Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pharm, Huaihai West Rd, Shanghai 200030, Peoples

Fudan Univ, Huashan Hosp, Dept Pharm, Shanghai, Peoples R China

Jiangsu Hengrui Med Co Ltd, Dept Clin Pharmacol, Shanghai, Peoples R China

2021

10.1016/j.ejps.2021.105729

European journal of pharmaceutical sciences

European journal of pharmaceutical sciences

ISTP
ISSN：0928-0987
年,卷(期)：2021.159
  • 1
  • 22